ABX196

In the melanoma model, immune response evaluation included immunofluorescence staining and detection by flow cytometry to identify anti-CD45, anti-CD8, anti-CD4, anti-CD3, anti-CD19, anti-FoxP3, CD1d tetramer, and anti-PD-1 markers. A synergistic combination effect was apparent when interferon-γ was measured in peripheral blood, indicating sustained activation of iNKT cells. In both models, the anti-tumor effects were associated with a generation of a more advantageous T-effector to Treg cell ratio within the tumor, which could lead to in the proliferation and accumulation of cells that would otherwise be anergized.

P1/2, N=48, Recruiting, Abivax S.A. | Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2021